EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
3.4.22.52 | Carcinoma |
1426051 |
A comparison of the intracellular distribution of mu-calpain, m-calpain, and calpastatin in proliferating human A431 cells. |
unassigned |
0 |
3.4.22.52 | Cataract |
1440613 |
Comparison of cell-permeable calpain inhibitors and E64 in reduction of cataract in cultured rat lenses. |
causal interaction ongoing research therapeutic application unassigned |
2 2 4 0 |
3.4.22.52 | Cataract |
1608594 |
Hydration and elevated calcium alone do not produce xylose nuclear cataract: role of proteolysis by calpain. |
causal interaction diagnostic usage ongoing research therapeutic application |
3 1 3 1 |
3.4.22.52 | Cataract |
1848210 |
Amelioration of cataracts and proteolysis in cultured lenses by cysteine protease inhibitor E64. |
causal interaction ongoing research therapeutic application unassigned |
4 2 4 0 |
3.4.22.52 | Cataract |
2209751 |
Calpain II in two in vivo models of sugar cataract. |
diagnostic usage ongoing research therapeutic application unassigned |
4 2 1 0 |
3.4.22.52 | Cataract |
2998702 |
Age-related changes of calpain II and alpha-crystallin in the lens of hereditary cataract (Nakano) mouse. |
causal interaction ongoing research therapeutic application unassigned |
4 1 1 0 |
3.4.22.52 | Neoplasms |
2999095 |
Hydrolytic and autolytic behavior of two forms of calcium-activated neutral protease (CANP). |
unassigned |
0 |
3.4.22.52 | Neoplasm Metastasis |
6873970 |
Establishment, characterization, and response to cytotoxic and radiation treatment of three human melanoma cell lines. |
ongoing research therapeutic application unassigned |
2 1 0 |
3.4.22.52 | Neoplasms |
6873970 |
Establishment, characterization, and response to cytotoxic and radiation treatment of three human melanoma cell lines. |
ongoing research therapeutic application unassigned |
2 1 0 |
3.4.22.52 | Brain Ischemia |
7643117 |
Eukaryotic initiation factor 4E degradation during brain ischemia. |
causal interaction therapeutic application unassigned |
1 1 0 |